Ischemic preconditioning requires opening of pannexin-1/P2X(7) channels not only during preconditioning but again after index ischemia at full reperfusion.
Protection of the ex vivo rat heart from ischemia/reperfusion injury can be provided by ischemic preconditioning (IPC). Previous studies revealed that a complex of pannexin-1 with the P2X₇ receptor forms a channel during IPC that results in the release of cardioprotectants such as adenosine and sphingosine 1-phosphate (S1P) that bind to G-protein-coupled cell surface receptors triggering cardioprotective cell signaling pathways. Antagonists of both pannexin-1 (carbenoxolone and mefloquine) and P2X₇ receptors (brilliant blue G) are known to block IPC when administered at the time of preconditioning (Vessey et al. J Cardiovasc Pharmacol Ther 15:190, 2010). We now demonstrate that these same antagonists also block the cardioprotective effects of IPC when added after the index ischemia during full reperfusion. Likewise, addition at full reperfusion of binding antagonists to the endogenous cardioprotectants S1P (VPC) or adenosine (8-SPT) reduced the effectiveness of IPC. These data suggest that IPC has a component that requires the release of cardioprotectants via pannexin-1/P2X₇ channels not only during preconditioning phase but again during the early stages of reperfusion following the index ischemia. It was found that the level of cardioprotectant release required at reperfusion to achieve cardioprotection was lower when hearts had been preconditioned. Further, pharmacologic preconditioning with S1P or adenosine was also blocked at reperfusion by antagonists of the pannexin-1/P2X₇ channels indicating that pharmacologic preconditioning also requires opening of the channel at full reperfusion. In untreated hearts, key components of the PI3 kinase/Akt signaling pathway were revealed by western analysis to be lost during ischemia. This correlates with an inability to generate phospho-Akt at reperfusion. IPC prevents this loss and thereby primes the cell for response to cardioprotectants released at full reperfusion.
Department of Veterans Affairs Medical Center, Liver Study Unit (151-K), 4150 Clement St., San Francisco, CA 94121, USA. donald.vessey@va.gov
Donald A
DA
Vessey
Luyi
L
Li
Michael
M
Kelley
D000818:Animals; D015153:Blotting, Western; D017630:Connexins / Q000502:physiology*; D019157:Ischemic Preconditioning, Myocardial; D008297:Male; D009419:Nerve Tissue Proteins / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D058486:Receptors, Purinergic P2X7 / Q000502:physiology*; D015427:Reperfusion Injury
D017630:Connexins; D009419:Nerve Tissue Proteins; D058486:Receptors, Purinergic P2X7; C479936:pannexin 1, rat
Cardiovasc Res. 2006 May 1;70(2):200-11
16545349
J Biochem Mol Toxicol. 2008 Mar-Apr;22(2):113-8
18418901
Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H441-9
16155103
Oxid Med Cell Longev. 2009 Jul-Aug;2(3):146-51
20592769
Circ Res. 1990 Apr;66(4):913-31
2317895
Trends Cardiovasc Med. 2005 Feb;15(2):69-75
15885573
FEBS Lett. 2007 Feb 6;581(3):483-8
17240370
Cardiovasc Res. 2006 May 1;70(2):212-21
16448635
Circulation. 1990 Dec;82(6):2044-51
2242528
FASEB J. 2002 Feb;16(2):135-46
11818361
Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1429-35
19648253
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
15784165
Eur Heart J. 1995 Jun;16(6):734-40
7588916
Am J Physiol Cell Physiol. 2009 Feb;296(2):C250-5
18945939
Physiol Rev. 2008 Apr;88(2):581-609
18391174
Med Sci Monit. 2006 Oct;12(10):BR318-24
17006394
Int J Cardiol. 1997 Jan 31;58(2):95-117
9049675
Circulation. 1998 Oct 6;98(14):1355-7
9760287
Cardiovasc Res. 2002 Aug 15;55(3):438-55
12160941
Annu Rev Med. 1991;42:225-46
2035969
Basic Res Cardiol. 2008 May;103(3):203-15
17999026
Cardiovasc Res. 1998 Oct;40(1):74-87
9876319
Cardiovasc Res. 2009 May 1;82(2):250-60
19147653
Biochem Biophys Res Commun. 2008 Oct 24;375(3):425-9
18706887
J Mol Cell Cardiol. 2007 Sep;43(3):262-71
17632123
J Biochem Mol Toxicol. 2007;21(5):273-9
17912702
Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H971-6
15358610
J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):190-5
20200324